New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 6, 2014
07:00 EDTAERIAerie Pharmaceuticals shares should be bought ahead of data, says Stifel
After traveling with Aerie's management, Stifel believes there is a good chance that the Phase 2b data for the company's Roclatan will be positive. The firm expects the data to be released in late June/early July, and it recommends buying shares of Aerie ahead of the data release. It keeps a $24 price target and Buy rating on the shares.
News For AERI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 25, 2015
10:00 EDTAERIOn The Fly: Analyst Initiation Summary
Subscribe for More Information
March 24, 2015
16:06 EDTAERIAerie Pharmaceuticals initiated with a Buy at Brean Capital
Subscribe for More Information
06:02 EDTAERIAerie Pharmaceuticals completes enrollment for Phase 3 trial of Rhopressa
Aerie Pharmaceuticals announced the completion of enrollment in the Company’s second Phase 3 registration trial of Rhopressa, a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure,or IOP, in patients with glaucoma or ocular hypertension. Rocket 2 will measure efficacy over three months, as well as safety over one year. The primary efficacy endpoint of the trial is to demonstrate non-inferiority of IOP lowering for Rhopressa compared to timolol.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use